ArticleBulletin of experimental biology and medicine2026
Comparative Analysis of the Effect of Uridine on Oxidative and Energy Metabolism in the Blood during Administration of Rotenone and 6-Hydroxydopamine in Rats.
Article in Bulletin of experimental biology and medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We investigated the effect of the nucleoside uridine on the activities of key enzymes of oxidative phosphorylation (succinate dehydrogenase, SDH) and glycolysis (lactate dehydrogenase, LDH) in peripheral blood lymphocytes, and on oxidative metabolism in the blood serum of rats in the rotenone and 6-OHDA models of Parkinson's disease. Both models were characterized by increased SDH and LDH activities in lymphocytes and accumulation of lipid peroxides in the blood serum. Injections of uridine, affecting the functioning of mitochondrial K-ATP channel (mitoKATP), to animals at a dose of 30 mg/kg body weight for 28 days mitigated SDH and LDH hyperactivation in lymphocytes and reduced the serum level of LPO products. Specific mitoKATP inhibitor 5-hydroxydecanoate (5 mg/kg) eliminated the effect of uridine. The role of mitoKATP in the protective effect of uridine in a model of Parkinson's disease is discussed.
Indexed as
Identifiers
41944949What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.